Dr Kalesnykas earned his PhD in Neuroscience in 2005 from the University of Kuopio and completed several postdoctoral fellowships studying the pathophysiology of glaucoma and ocular gene therapy. He currently serves as an Adjunct Professor of Experimental Ophthalmology at University of Tampere, Finland.
In 2009, Dr Kalesnykas was awarded the prestigious position of Finnish Academy Research Fellow, which he held until 2013. He was a visiting researcher at the Wilmer Eye Institute at The Johns Hopkins University from 2010-2011. In 2013, he founded Experimentica Ltd., which under his leadership has grown to become one of the leading preclinical CROs dedicated to drug discovery and development for ophthalmic disorders.